Európai Unió - norvég - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatitt, atopisk - andre dermatologiske preparater - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Európai Unió - norvég - EMA (European Medicines Agency)

theramex ireland limited - linzagolix choline - leiomyomer - hypofysiske og hypotalamiske hormoner og analoger - yselty is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Európai Unió - norvég - EMA (European Medicines Agency)

novo nordisk a/s - semaglutide - obesity; overweight - antiobesity preparater, ekskl. diettprodukter - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to.

Európai Unió - norvég - EMA (European Medicines Agency)

vbi vaccines b.v. - hepatitt b overflate antigen - hepatitt b - vaksiner - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.

Európai Unió - norvég - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - andre hjertepreparater - treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Európai Unió - norvég - EMA (European Medicines Agency)

ultragenyx germany gmbh - evinacumab - hyperkolesterolemi - lipid modifiserende midler - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).

Európai Unió - norvég - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastiske midler - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Európai Unió - norvég - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - multippel sklerose, relapsing-remitting - immunsuppressive - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

Európai Unió - norvég - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - karsinom, ikke-småcellet lunge - antineoplastiske midler - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Európai Unió - norvég - EMA (European Medicines Agency)

novartis ireland ltd - ofatumumab - multippel sklerose, relapsing-remitting - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.